Inflammation Scores Predict the Survival of Patients With Hepatocellular Carcinoma Who Were Treated With Transarterial Chemoembolization and Recombinant Human type-5 Adenovirus H101

PLoS One. 2017 Mar 29;12(3):e0174769. doi: 10.1371/journal.pone.0174769. eCollection 2017.

Abstract

Background: The systemic inflammatory response plays an important role in cancer development and progression. An original inflammation-based staging system for predicting survival in patients undergoing transarterial chemoembolization (TACE) combined with recombinant human type-5 adenovirus H101 is not available. This study aimed to validate the prognostic value of inflammation scores for patients with hepatocellular carcinoma (HCC) who were treated with TACE combined with H101.

Methods: The data from 216 patients with HCC who underwent TACE combined with H101 from January 2007 to July 2015 were retrospectively collected, and the association of the inflammation scores with overall survival (OS) was analyzed. Univariate and multivariate analyses were performed to identify variables associated with OS. The prognostic value of the inflammation scores, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), neutrophil/ platelet-to-lymphocyte ratio (NLR-PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PNI), prognostic index (PI), tumor-node-metastasis (TNM), Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) staging systems were analyzed and compared using the areas under the receiver operating characteristic curves (AUROCs).

Results: The estimated 1-, 2-, and 3-year OS rates were 61.3%, 44.2%, and 40.5% for the entire study cohort, respectively; the median OS was 17 months. According to the multivariate Cox proportional hazards model, the pretreatment NLR, tumor diameter and pretreatment alpha-fetoprotein (AFP) levels were independent predictors of OS. The CLIP score had superior discriminative abilities compared with other staging systems, and the NLR-PLR score consistently displayed a higher AUROC value than the other inflammation-based prognostic scores. The combination of the NLR-PLR and CLIP scores exhibited a superior prognostic ability for OS compared to the NLR-PLR or CLIP scores alone.

Conclusions: The NLR-PLR score is a more powerful predictive system than the other inflammation-based scores for patients with HCC who were treated with TACE and H101. The predictive ability may be improved by utilizing a combination of the NLR-PLR and CLIP scores.

MeSH terms

  • Adenoviruses, Human / genetics
  • Adenoviruses, Human / immunology
  • Adenoviruses, Human / physiology
  • Adult
  • Aged
  • Blood Platelets / immunology
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / therapy*
  • Carcinoma, Hepatocellular / virology
  • Chemoembolization, Therapeutic / methods*
  • Combined Modality Therapy
  • Female
  • Humans
  • Inflammation / diagnosis*
  • Inflammation / immunology
  • Kaplan-Meier Estimate
  • Leukocyte Count
  • Liver Neoplasms / immunology
  • Liver Neoplasms / therapy*
  • Liver Neoplasms / virology
  • Lymphocytes / immunology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neutrophils / immunology
  • Oncolytic Virotherapy / methods*
  • Oncolytic Viruses / genetics
  • Oncolytic Viruses / immunology
  • Oncolytic Viruses / physiology
  • Platelet Count
  • Prognosis
  • Retrospective Studies
  • Young Adult

Grant support

The authors received no specific funding for this work.